---
schema_version: "secwatch.filing_event.v1"
accession: "0001808805-24-000004"
form_type: "8-K"
ticker: "NAUT"
cik: "0001808805"
company_name: "Nautilus Biotechnology, Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T09:20:04.805081+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nautilus Biotechnology reports FY2023 net loss $63.7M; cash runway into H2 2026

## Summary
- Net loss $63.7M for FY2023, compared to $57.9M in FY2022; operating expenses $76.2M, up 20% YoY.
- Cash, equivalents and investments $264.1M as of Dec 31, 2023; expected runway into second half 2026.
- FY2024 operating expense expected to grow ~25% vs 2023.
- Platform launch (instruments, consumables, software) planned for 2025.
- CEO Sujal Patel cited fiscal discipline and progress on proprietary proteome analysis platform.

## SEC filing metadata
- accession: 0001808805-24-000004
- form_type: 8-K
- ticker: NAUT
- cik: 0001808805
- company_name: Nautilus Biotechnology, Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808805/000180880524000004/0001808805-24-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808805/000180880524000004/naut-20240228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808805-24-000004
- JSON: https://secwatch.observer/filing/0001808805-24-000004.json
- Plain text: https://secwatch.observer/filing/0001808805-24-000004.txt

## Key facts
- Earnings Releases
  Nautilus Biotechnology, Inc. updated its Fiscal Year 2024 Outlook guidance (initiated).
  - Period: Fiscal Year 2024 Outlook
  - Guidance: initiated
  - Result: guidance update
  source text: Fiscal Year 2024 Outlook • We expect full year operating expense to grow by approximately 25% relative to 2023 • We expect that cash and cash equivalents and investments of $264.1 million as of December 31, 2023 to provide a runway into the second half of 2026 • We expect to launch our platform, instruments, consumables, and software in 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808805/000180880524000004/0001808805-24-000004-index.htm
- Earnings Releases
  Nautilus Biotechnology, Inc. reported the fiscal year ended December 31, 2023 results: net income $63.7 million.
  - Period: the fiscal year ended December 31, 2023
  - Net income: $63.7 million
  - Result: reported results
  source text: Net loss was $63.7 million for the year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808805/000180880524000004/0001808805-24-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.